Introduction
Azacitidine is a ring analog of the pyrimidine nucleoside cytidine, with therapeutically useful effects on cell differentiation, gene expression and DNA synthesis and metabolism. 1 Azacitidine inhibits methylation of newly synthesized DNA by inhibiting DNA methyltransferase activity. [2] [3] [4] Aberrant DNA methylation (hypermethylation) results in silencing of genes responsible for cell growth control and differentiation, and has been associated with cancers, including MDS, and other hematologic malignancies. [5] [6] [7] [8] [9] Azacitidine is believed to exert its antineoplastic effects, in part, by inducing DNA hypomethylation. [10] [11] [12] [13] [14] Induction of DNA hypomethylation may restore normal function to genes that are critical for differentiation and proliferation. 5, 15, 16 The goal of pharmaceutical intervention is to provide maximum therapeutic effectiveness with minimum risk to subjects. Orally administered medications allow for convenient dosing, but, because of gastrointestinal absorptive barriers, enzyme activity and interactions with other ingested substances, achieving therapeutic plasma levels of active drug by this route is sometimes challenging. This is particularly important for azacitidine, which is thought to be degraded in the intestinal tract by spontaneous hydrolysis and, enzymatically, by cytidine deaminase. 17 Until recently, attempts to develop an oral formulation of pyrimidine nucleosides have been unsuccessful because of intestinal degradation. An oral formulation of azacitidine will be more convenient for patients, facilitate long-term dosing, reduce the potential for local side effects associated with subcutaneous (s.c.) injection, and, allow for the evaluation of alternative doses and schedules. It is hypothesized that continuous (low-dose) oral azacitidine administration may provide more persistent DNA hypomethylation, translating to superior or differentiated efficacy compared to that seen with the parenteral formulation.
Recently, a new formulation of oral azacitidine has been developed that is orally bioavailable in a canine model. 18 Based on these data, a pilot phase 1 feasibility study was conducted in subjects with MDS, leukemia or solid tumors to assess the oral bioavailability and safety of this new oral formulation of azacitidine.
Methods
The objectives of this study were: (1) to obtain initial information on the oral bioavailability of azacitidine administered as a filmcoated tablet; (2) to assess the safety and tolerability of escalating doses of orally administered azacitidine and (3) to gather preliminary information on the single-dose pharmacokinetics of azacitidine after oral administration.
Drug formulation
Oral azacitidine was supplied as 20 mg film-coated tablets manufactured by Azopharma in Miramar, FL, USA.
Study design
This was an open-label, single-treatment, escalating-dose, pharmacokinetic study in which single-subject cohorts were treated with escalating oral doses of azacitidine in 20 mg increments. Subjects were to receive only one dose of azacitidine. Dosing began with the first subject receiving a dose of 60 mg (three 20 mg tablets). If tolerated, the dose was to be escalated in a second subject by 20 mg (total of 80 mg) and then subsequent subjects until one of the following conditions was met: (1) drug administration was deemed intolerable; (2) the appropriate concentrations of drug were found in plasma or (3) dose escalation reached the 200 mg level, which is approximately equivalent to the maximum approved daily dose of subcutaneous azacitidine (that is, 100 mg/m 2 ).
'Appropriate concentrations of drug in plasma' were defined as at least four consecutive timed samples containing quantifiable concentrations of azacitidine from which pharmacokinetic assessments could be made. After appropriate concentrations of azacitidine were found in plasma, the same dose was administered to 1-2 additional subjects to verify results.
Azacitidine treatment was deemed intolerable if a subject experienced any Grade 3 or 4 adverse event possibly related to azacitidine or a significant safety concern was identified following treatment. If a subject was found to be intolerant, a second or third subject was treated at the same dose level to confirm intolerance. If no safety concerns were identified and no Grade 3 or 4 adverse events occurred, then dose escalation could continue until appropriate concentrations of plasma azacitidine were found (or a maximum dose of 200 mg was reached).
Pharmacokinetics
Blood samples for the determination of plasma azacitidine concentrations were collected on day 1 prior to dosing and at the following time points after dosing: 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8 and 10 h, (and 12 h, if possible). Plasma was harvested and subsequently analyzed for azacitidine concentrations using a validated high-performance liquid chromatography/tandem mass spectrometric method (LC-MS/ MS) (unpublished observation).
Azacitidine plasma concentration versus time data were used to calculate pharmacokinetic parameters using non-compartmental methods. Parameters calculated included C max , T max , T 1/2 , AUC(0-t) and AUC(0-N). Bioavailability (F%) was determined relative to historic pharmacokinetic data following s.c. treatment with azacitidine at a dose of 75 mg/m 2 , approximately equal to 135 mg/day, based on a 1.8 m 2 body surface area. 18 
Subjects
Male or female subjects with MDS, AML or malignant solid tumors who were X18 years of age, had an Eastern Cooperative Oncology Group performance status of 0-2 and who signed a study-specific informed consent document were eligible for participation in the study. For subjects with AML or malignant solid tumors, eligibility was limited to those for whom standard curative or palliative measures did not exist or were no longer effective. Renal, hepatic and gastrointestinal parameters were required to be within normal limits. The study did not include subjects who were pregnant, had a history of severe cardiac or pulmonary disease, had advanced malignant hepatic tumors or who had received radiation therapy, chemotherapy or investigational drugs within 30 days of study onset. The study met institutional guidelines for both clinic centers.
Results
Four subjects were treated with single doses of oral azacitidine, one subject at 60 mg and three at 80 mg. Azacitidine concentrations were detected in plasma of all four subjects. Thus, the primary study endpoint was met and the study was complete (Table 1) .
Pharmacokinetic results
Quantifiable plasma concentrations of azacitidine were found in the 60 mg subject, but plasma samples measured post-C max were too sparse to calculate pharmacokinetic parameters. Thus, dose escalation to 80 mg followed. After determining adequate blood levels in this second subject, two additional subjects were treated at the 80 mg level. All three subjects treated at 80 mg had quantifiable azacitidine in plasma at multiple time points, allowing for valid ascertainment of pharmacokinetic parameters (Tables 2 and 3) . Maximum azacitidine plasma concentrations were reached at 3 h for the subject dosed at 60 mg and at a mean time of 1.5 h (range 1-2 h) for those dosed at 80 mg. The historical T max for a s.c. dose of 135 mg is 0.5 h (the first sampling point that was employed in the study). 19 The mean maximum plasma concentration for those treated orally with 80 mg azacitidine was 64.4 ng/ml (range 26.9-91.1), which is 8.5% of the C max for a s.c. dose of 135 mg (Table 2 ) and approximately fourfold higher than that for the 60 mg oral dose. Mean plasma half-life for the oral 80 mg dose was 0.389 h compared to 0.68 h for the s.c. 135 mg dose. Bioavailability of the oral dose was 17.4% relative to the s.c. 135 mg dose (Table 3) . Figure 1 illustrates in log scale the plasma azacitidine concentration versus time profiles of the orally treated subjects in the present study compared to the profile following s.c. 75 mg/m 2 (135 mg) dosing. Using computer simulation of the plasma concentrations and overall drug exposure observed in this study, the azacitidine pharmacokinetic profile at doses of up to 600 mg remains below that seen with s.c. administered azacitidine at 75 mg/m 2 /day.
Safety
Oral azacitidine was well tolerated by all four subjects. Serious adverse reactions were not observed in any subject during the 10±3 day post-dose observation period, and most adverse events emerging during this time frame were not considered related to azacitidine. Two exceptions were headache and vomiting (possibly related) reported for subject 1 (60 mg azacitidine). Most adverse events were rated mild or moderate and resolved with no treatment. One subject treated at 80 mg experienced serious adverse events (staphylococcal bacteremia, decreased platelets and decreased hemoglobin) 24 days Pharmacokinetics of oral azacitidine G Garcia-Manero et al post-dosing, which were considered life threatening and required hospitalization. These were not related to azacitidine treatment. Table 4 summarizes treatment emergent adverse events observed during the study. Further investigation of increasing doses of oral azacitidine administered with sequential daily dosing is needed to determine the safety profile of oral azacitidine.
Discussion

Vidaza (azacitidine for injection) is approved in the United
States for treatment of all French-American-British subtypes of MDS and has demonstrated activity in the treatment of AML. 20 Silverman et al. 21 demonstrated prolonged time to AML transformation in elderly patients with refractory anemia with excess blasts and refractory anemia with excess blasts in transition to AML and a trend for prolonged survival following azacitidine therapy. These results were confirmed by a recent study in 358 high-risk MDS patients, which showed statistically significant (P ¼ 0.0001) greater overall survival with azacitidine treatment (24.4 months) compared to a conventional care regimen (15 months). 22 Current dosing is by s.c. injection or intravenous (i.v.) infusion with a regimen of 75 mg/m 2 for 7 days every 28 days. Several studies have shown diminished parenteral azacitidine-induced DNA demethylation by the end of a 4-week treatment cycle. [23] [24] [25] Oral azacitidine bioavailability has been examined in dogs and rats. A comparison of oral azacitidine (6 mg/kg) to s.c. and i.v. dosing (2 mg/kg) in dogs showed rapid absorption by the oral route (T max ¼ 15 min), with absolute bioavailability of 67% (compared to 71% following s.c. dosing). Absolute oral bioavailability in rats was 47%. 18 Preexisting human oral bioavailability data for azacitidine is limited. Three reports of oral azacitidine administration include one patient who received 2 mg azacitidine three times daily for 5 days for the treatment of b-thalassemia, 26 and two sickle cell patients who received 0.2 mg/kg/day 3 days per week for up to 28 weeks. 27, 28 In both studies, the cytidine deaminase inhibitor Pharmacokinetics of oral azacitidine G Garcia-Manero et al tetrahydrouridine was co-administered with azacitidine. In the patient with b-thalassemia, no increase in total hemoglobin levels was observed, but at the time of therapy the patient was in an advanced disease state. In the sickle cell patients, a rapid and maintained elevation of total hemoglobin, fetal hemoglobin and F cells was observed for the duration of therapy. These data suggest the drug is orally available and exerts systemic effects. At the administered dose of 0.2 mg/kg/day with co-administration of 200 mg of tetrahydrouridine, no evidence of cytotoxicity was observed.
In this pilot study, we have demonstrated that an oral formulation of azacitidine can be absorbed in humans and provide detectable levels of azacitidine in plasma. An observable delay in absorption with oral dosing was apparent and thought to be a function of the film-coated tablet formulation.
It can be concluded from this study that single oral doses of azacitidine (up to 80 mg) are bioavailable, safe and well tolerated. However, high oral doses may be required to overcome potential absorptive limitations of gastrointestinal administration and reach a clinically significant therapeutic effect. A multi-dose phase 1 study to further evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral azacitidine is currently ongoing. Continuous oral dosing of azacitidine may be a feasible alternative to s.c. dosing, providing greater ease of administration, allowing the possibility of a more sustained maximum therapeutic effect and eliminating local injection site reactions.
